Journal ID (nlm-ta): F1000Res
Journal ID (iso-abbrev): F1000Res
Journal ID (pmc): F1000Research
Title:
F1000Research
Publisher:
F1000 Research Limited
(London, UK
)
ISSN
(Electronic):
2046-1402
Publication date
(Electronic):
3
December
2018
Publication date Collection: 2018
Volume: 7
Electronic Location Identifier: F1000 Faculty Rev-1889
Affiliations
[1
]Cell Signalling and Cell Death, The Walter and Eliza Hall Institute of Medical Research,
Melbourne, Victoria, 3052, Australia
[2
]Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, 3050,
Australia
Author notes
Competing interests: DLV was on the scientific advisory board of TetraLogic, and he and NL have patent
applications related to birinapant.
Author information
Article
DOI: 10.12688/f1000research.16439.1
PMC ID: 6281012
SO-VID: c50dcc09-a3b1-4897-80be-a67c04ec7688
Copyright © Copyright: © 2018 Lalaoui N and Vaux DL
License:
This is an open access article distributed under the terms of the Creative Commons
Attribution Licence, which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Funded by: Cancer Australia and Cure Cancer Australia Foundation
Award ID: Projectgrant#1145588toNL
Funded by: National Health and Medical Research Council
Award ID: ProgramGrant#1113133toDLV
Funded by: Victorian Cancer Agency
Award ID: Fellowship#17030toNL
Funded by: National Health and Medical Research Council
Award ID: Fellowship#1020136toDLV
Funded by: Australian Government Independent Medical Research Institutes Infrastructure Support
Scheme (IRIISS)
Funded by: Leukemia and Lymphoma Society SCOR
Award ID: Projectgrant#7001-13toDLV
Funded by: Victorian State Government Operational Infrastructure Support (OIS).
This work was supported by project grant #1145588 from the Cancer Australia and Cure
Cancer Australia Foundation (to NL), Victorian Cancer Agency Mid-career Fellowship
#17030 (to NL), Australian National Health and Medical Research Council (NHMRC) Program
Grant #1113133 (to DLV), NHMRC Fellowship #1020136 (to DLV), and Leukemia and Lymphoma
Society SCOR grant #7001-13 (to DLV). This work was made possible by operational infrastructure
grants through the Australian government’s Independent Research Institute Infrastructure
Support Scheme and the Victorian state government’s Operational Infrastructure Support.
The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.